Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation — Stella
Home / Delayed Graft Function / Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation View on ClinicalTrials.gov Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
(130 sites) United States
Research Site, Phoenix, Arizona Research Site, Los Angeles, California Research Site, San Francisco, California Research Site, San Francisco, California Research Site, Stanford, California Research Site, New Haven, Connecticut Research Site, Jacksonville, Florida Research Site, Tampa, Florida Research Site, Atlanta, Georgia Research Site, Chicago, Illinois Research Site, Chicago, Illinois Research Site, Fairway, Kansas Research Site, Lexington, Kentucky Research Site, Kenner, Louisiana Argentina
Research Site, Buenos Aires Research Site, Buenos Aires Research Site, Buenos Aires Research Site, Capital Federal Australia
Research Site, Camperdown Brazil
Research Site, Belo Horizonte Research Site, Belo Horizonte Research Site, Porto Alegre Research Site, Porto Alegre Research Site, Rio de Janeiro Research Site, São José do Rio Preto Canada
Research Site, Edmonton, Alberta Research Site, Vancouver, British Columbia Research Site, Toronto, Ontario Research Site, Toronto, Ontario Research Site, Montreal, Quebec Czechia
Research Site, Hradec Kralova France
Research Site, La Rochelle Research Site, La Tronche Research Site, Montpellier Germany
Research Site, Mainz Am Rhein South Korea
Research Site, Gyeonggi-do Taiwan
Research Site, Kaohsiung City Research Site, Taoyuan District United Kingdom
Research Site, Woodville South
Key details Sponsor
Alexion Pharmaceuticals, Inc.
Enrollment target
~450 participants
Primary completion
February 2028
Age range
18 Years and older
Last updated April 2026
Interested in joining? Research Site, Ann Arbor, Michigan
Research Site, Detroit, Michigan Research Site, Minneapolis, Minnesota Research Site, St Louis, Missouri Research Site, Omaha, Nebraska Research Site, Livingston, New Jersey Research Site, New York, New York Research Site, New York, New York Research Site, Durham, North Carolina Research Site, Philadelphia, Pennsylvania Research Site, Greenville, South Carolina Research Site, Nashville, Tennessee Research Site, Dallas, Texas Research Site, Houston, Texas Research Site, Charlottesville, Virginia Research Site, Richmond, Virginia Research Site, Seattle, Washington Research Site, Milwaukee, Wisconsin